Treatment of cancer with dual targeting of CD47 and EGFR

Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used..

Medienart:

Patent

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Europäisches Patentamt - (2019) vom: 09. Juli Zur Gesamtaufnahme - year:2019

Sprache:

Englisch

Beteiligte Personen:

WEISSMAN IRVING L [VerfasserIn]
WILLINGHAM STEPHEN [VerfasserIn]
HO DORIS PO YI [VerfasserIn]
DALERBA PIERO D [VerfasserIn]
MCKENNA KELLY MARIE [VerfasserIn]
VOLKMER JENS-PETER [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2019-07-09, Last update posted on www.tib.eu: 2023-08-01, Last updated: 2023-08-04

Patentnummer:

US10344094

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA002861356